VistaGen Therapeutics Inc. has announced its financial results for the fiscal year 2026 first quarter, which ended on June 30, 2025. The company reported a net loss of $15.1 million, an increase from the $10.7 million net loss in the same period the previous year. Research and development expenses rose to $11.7 million, up from $7.6 million year-over-year, primarily due to increased costs associated with the U.S. registration-directed PALISADE Program for fasedienol in social anxiety disorder (SAD). General and administrative expenses slightly decreased to $4.4 million from $4.6 million in the prior year. As of June 30, 2025, VistaGen held cash, cash equivalents, and marketable securities totaling $63.2 million. The company continues to advance its intranasal pherine pipeline, targeting treatments in psychiatry, women's health, and cancer supportive care. Topline results from the PALISADE-3 Phase 3 trial of fasedienol for the acute treatment of SAD are expected in the fourth quarter of 2025, with results from the PALISADE-4 Phase 3 trial anticipated in the first half of 2026.